Introduction

Lung cancer is one of the leading causes of cancer-related death worldwide, accounting for an estimated 1.6 million deaths each year.\(^1\) Non-small cell lung cancer (NSCLC) represents 85% of lung cancer diagnoses.\(^2\) Approximately 40% of patients with NSCLC initially present with metastatic disease\(^3\) and nearly half of patients with locally advanced disease develop distant metastases despite aggressive treatment with chemoradiation.\(^4\) NSCLC most commonly metastasizes to the brain, bone, lung, adrenal gland, and liver. Splenic involvement occurs in only 1%-6% of lung cancer\(^5,6\) and is usually part of an extensive metastatic process.\(^6,7\) Although stereotactic body radiation therapy (SBRT) is frequently used to treat a limited number of metastases (up to 5) in oligometastatic NSCLC, the role of aggressive metastasis-directed treatment in diffuse metastatic disease is not well established.\(^8,9\) The case presented here describes a progressive splenic metastasis from NSCLC treated with SBRT to achieve a durable complete tumor response in the setting of widespread, but otherwise stable systemic disease while on immunotherapy with nivolumab.

Case presentation

An 80-year-old woman with a 40-pack-year smoking history but no major medical comorbidities presented with an enlarging left parotid mass. Preoperative workup for removal of the mass revealed a 32 mm left lower lobe lung nodule with lesions in the liver, bones, brain, and spleen, highly suggestive of a primary lung malignancy with diffuse metastases. Computed tomography (CT)—guided biopsy of a liver lesion demonstrated moderately to poorly differentiated adenocarcinoma of the lung. No alterations in EGFR, ALK, or ROS1 genes were detected. Fine-needle aspiration of the left parotid mass confirmed metastatic involvement. Although her splenic lesion was not biopsied, a 30 mm round hypodense area in the spleen on CT imaging was radiographically consistent with a metastasis.

Given her metastatic disease and unknown PD-L1 status, she initially underwent 6 cycles of chemotherapy with carboplatin and pemetrexed and had a partial
response in the primary lung and hepatosplenic lesions. The brain metastasis was treated by stereotactic radiosurgery. After switching to maintenance pemetrexed, there was significant hepatosplenic progression and she was initiated on immunotherapy with nivolumab. During the first 9 months on nivolumab, there was a partial response in the hepatosplenic disease but progression in the brain and multiple bony sites, which were treated with stereotactic radiosurgery and external beam radiation therapy, respectively. For the next 8 months on nivolumab, she had stable disease in other sites but had isolated progression in the spleen (Fig 1A). Given her otherwise stable disease on nivolumab and desire to avoid cytotoxic chemotherapy, the decision was made to treat her splenic metastasis with SBRT while continuing nivolumab. In addition, although not necessarily expected in her case given the mixed response to nivolumab, consideration was given to the small chance of an abscopal effect which has been seen with SBRT and immunotherapy.10

A fiducial marker was placed in the splenic lesion for image-guided treatment. A wing board and VacQfix cushion were used to ensure proper positioning and immobilization. A high-resolution fine-cut contrast-enhanced 4-dimensional CT was taken. An abdominal magnetic resonance imaging was fused to the planning CT scan to aid in tumor volume delineation. The gross tumor volume was drawn. An internal target volume was treated with stereotactic radiosurgery and external beam radiation therapy, respectively. Orthogonal

**Figure 1** Splenic mass before stereotactic body radiation therapy (SBRT) and radiation plan. (A) Abdominal computed tomography showing a hypodense 36 mm × 26 mm lesion (arrow) in the spleen. SBRT plan to the splenic metastasis in (B) coronal and (C) axial view. Blue is internal target volume and red is planning target volume (PTV). The isodose lines representing the percentages of prescribed radiation therapy are indicated in the corresponding colors; yellow is 100%, purple is 80%, and brown is 50% isodose. PTV was planned to ensure 100% of the PTV received at least 95% of the prescription dose. Maximum dose heterogeneity was set at 107%.

**Table 1** Summary of radiation treatment plan for the splenic metastasis

| Metrics            | Desired | Achieved |
|--------------------|---------|----------|
| PTV V100% Rx       | ≥95%    | 95.0%    |
| Min >95% Rx        |         | 75.9% Rx |
| Colon V25 Gy       | <20 cm³ | 0.0 cm³  |
| D0.035 cm³         | <38 Gy  | 9.5 Gy   |
| Max <38 Gy         |         | 12.7 Gy  |
| Cord V14.5 Gy      | <1.2 cm³| 0.4 cm³  |
| V23 Gy <0.35 cm³   |         | 0.0 cm³  |
| D0.035 cm³         | <30 Gy  | 15.7 Gy  |
| Max <30 Gy         |         | 16.3 Gy  |
| Esophagus V19.5 Gy | <5 cm³  | 0.0 cm³  |
| D0.035 cm³         | <35 Gy  | 16.5 Gy  |
| Max <35 Gy         |         | 17.6 Gy  |
| Kidneys, combined  | Mean    | <18 Gy   |
| Lungs V5 Gy        | <30%    | 1.3%     |
| V20 Gy             | <7%     | 0.0%     |
| Mean <4.5 Gy       |         | 0.5 Gy   |
| Ribs V35 Gy        | <1 cm³  | 0.7 cm³  |
| D0.035 cm³         | <43 Gy  | 43.0 Gy  |
| Max <43 Gy         |         | 46.8 Gy* |
| Skin D0.035 cm³    | <24 Gy  | 42.4 Gy* |
| Max <24 Gy         |         | 44.4 Gy* |
| Stomach D0.035 cm³| <32 Gy  | 30.4 Gy  |
| Max <32 Gy         |         | 36.6 Gy* |

**Table 1** Summary of radiation treatment plan for the splenic metastasis

**Abbreviations:** D0.035 mL = dose to 0.035 mL of organ of interest; PTV = planning target volume; Rx = prescription dose; V100% Rx = percent of target volume receiving 100% of the prescription dose; Vxx Gy = volume (cm³ or %) receiving xx Gy.

* Necessary for target coverage.
Anteroposterior and lateral x-rays) films and cone beam CT were taken daily to ensure proper positions.

A total of 50 Gy in 5 fractions was delivered to the splenic mass every other day using two 6 MV photon arcs. Details of the treatment plan are shown in Fig 1B-C and Table 1. The patient tolerated the SBRT well. There was initial pseudoprogression of the splenic mass at 1 month post-SBRT, but this was followed by partial and complete tumor response at 4 and 10 months respectively (Fig 2A-C). Twenty months after her SBRT, she remained without any recurrence or progression in the spleen or other body sites.

Complete blood counts of the patient before, during, and after SBRT are shown in Table 2 and Fig 3. Before treatment, she had moderate lymphopenia and mild thrombocytopenia likely secondary to her bony and splenic metastases. During her SBRT, she developed severe lymphopenia that lasted about 6 months post-SBRT before improving to mild lymphopenia by 14 months post-SBRT. Before her treatment, she had standard vaccinations, including pneumococcal vaccine, as part of her routine health maintenance, and she did not develop any infectious complications. Her platelet counts also slightly decreased during SBRT but improved to a normal count by 2 months post-SBRT.

Discussion

In this case presentation, SBRT was used to definitively treat the enlarging splenic metastasis despite disseminated disease given otherwise stable systemic disease on nivolumab, so that the patient could continue immunotherapy and avoid cytotoxic chemotherapy. SBRT was well tolerated and resulted in a complete tumor response, allowing the patient to remain on nivolumab without escalation of systemic therapy. This case suggests that SBRT may be used in oligoprogressive metastatic NSCLC with immunotherapy safely with durable local and systemic control.

Historically, the role of radiation therapy in metastatic NSCLC has been symptom palliation using lower-dose radiation. However, with evidence supporting a survival benefit with the use of metastasis-directed ablative therapy in oligometastatic disease, SBRT is now commonly used for NSCLC with a limited number of metastases (up to 5). SBRT to the liver, lung, and adrenal glands in oligometastatic NSCLC has been associated with excellent and durable control of treated metastases, with 2-year tumor control rates ranging from 50% to 90%. For widespread metastatic disease, the use of aggressive metastasis-directed therapy is largely experimental and not well established. In an oligoprogresive setting where disease progression is limited to only a few sites while on systemic therapy, several studies including one single arm prospective trial.
The present case is also one of the first detailed reports of a splenic metastasis from NSCLC successfully treated with SBRT. Splenic metastasis is often treated definitively by splenectomy in the setting of an isolated metastasis or oligometastatic disease.6,33,34 To our knowledge, only 4 cases of SBRT to splenic metastases have been reported in the medical literature, with 2 cases describing a partial and complete response, respectively.35-37 In the present case, SBRT of the splenic mass resulted in pseudoprogression at 1-month post-SBRT, followed by partial and complete response within 4 and 10 months, respectively. We suggest that SBRT is more favorable over splenectomy given its minimal morbidity, non-invasiveness, and appropriateness for poor surgical candidates.

However, splenic irradiation presents a unique challenge as it can lead to immunosuppression from functional hyposplenism and lymphopenia, potentially reducing the body’s anti-tumor immune response and increasing the risk for infection. Higher mean spleen radiation dose has been associated with post-irradiation lymphopenia,38-40 and SBRT-induced severe lymphopenia with an absolute lymphocyte count of less than 0.5 K/UL in lung cancer patients has been correlated with worse overall survival.41 In addition, splenic irradiation with 40 Gy has been shown to cause splenic atrophy and functional hyposplenism, placing patients at risk for developing pneumococcal sepsis.42,43 Our patient experienced a 6-month period of severe lymphopenia post-SBRT. However, she had an excellent tumor response and the non-irradiated sites of disease remained stable. She also did not develop any infectious complications, perhaps as she had been previously vaccinated against pneumococcal bacteria. Nevertheless, given the association between lymphopenia and inferior survival, radiation-induced lymphopenia should be considered when choosing and delivering splenic SBRT. Splenic SBRT may not be appropriate for patients with severe lymphopenia. A potential approach to minimize SBRT-induced lymphopenia is partial treatment (irradiation of only a portion of the lesion), which has been shown to achieve similar treated metastasis control compared with complete treatment in a prospective trial.44 Although the patient presented in this case was treated with SBRT, whether a lower dose conventional radiation could have achieved a similar tumor response and control with less severe lymphopenia is unknown. In addition to lymphopenia, thrombocytopenia is a potential side effect associated with splenic irradiation.45 However, in our case of SBRT to the spleen, only slight worsening of baseline mild thrombocytopenia was observed.

In summary, our case suggests that SBRT is a safe and effective treatment modality for splenic metastasis from NSCLC. We also observe that SBRT can be used to achieve durable local and systemic control (20 months) in oligoprogressive NSCLC while on immunotherapy, avoiding systemic therapy escalation to
cytotoxic chemotherapy. However, splenic irradiation results in lymphopenia, and the benefit of metastasis control achieved with splenic SBRT should be balanced against such toxicity. Patients undergoing splenic irradiation should be recommended to receive vaccinations similar to those undergoing splenectomy to decrease the risk of infection in the period of treatment-related lymphopenia.

References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446-454.
3. Carney DN, Hansen HH. Non-small-cell lung cancer: Stalemate or progress? New Engl J Med. 2000;343:1261-1262.
4. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIB or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-199.
5. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62:246-250.
6. Mitsimponas N, Mitsogianni M, Crespo F, et al. Isolated splenic metastasis from non-small-cell lung cancer: A case report and review of the literature. Case Rep Oncol. 2017;10:638-643.
7. Berge T. Splenic metastases. Frequencies and patterns. Acta Pathol Microbiol Scand A. 1974;82:499-506.
8. Iyengar P, Kavanagh BD, Wardak Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32:3824-3830.
9. Juan O, Popat S. Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 2017;18:595-606.
10. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011:2011:439752.
11. Rosenzweig KE, Chang JY, Chey TJ, et al. ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: Poor performance status or palliative intent. J Am Coll Radiol. 2013;10:654-664.
12. Palma DA, Olson RA, Harrow S, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): Results of a randomized trial. Int J Radiat Oncol Biol Phys. 2018;102:53-54.
13. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy (LCT) improves overall survival (OS) compared to maintenance therapy/observation in oligometastatic non-small cell lung cancer (NSCLC): Final results of a multicenter, randomized, controlled phase 2 trial. Int J Radiat Oncol Biol Phys. 2018:102:1604.
14. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase II/I trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572-1578.
15. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71-75.
16. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650-658.
17. Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cardenes HR. Long-term safety and efficacy of stereotactic body radiotherapy for hepatic oligometastases. Pract Radiat Oncol. 2016;6:86-95.
18. Lee MT, Kim JJ, Dinnell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585-1591.
19. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28-e37.
20. Gan GN, Weickhardt AJ, Scheier B, et al. Stereotactic radiation therapy can safely and durably control sites of extracranial new system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88:892-898.
21. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8:346-351.
22. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-1814.
23. Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY, Yeung RMW. The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: A matched-cohort analysis. Clin Oncol. 2017;29:568-575.
24. Qiu B, Liang Y, Li Q, et al. Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer. 2017;18:e369-e373.
25. Merino Lara T, Helou J, Poon I, et al. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy? Lung Cancer. 2018;124:219-226.
26. Patel FH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: Treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol). 2019;31:824-833.
27. Luo J, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36:1611-1618.
28. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumor burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65.
29. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small-cell lung cancer. Cancer Immunol Res. 2013;1:365-372.
30. Britschgi C, Riesterer O, Burger IA, Guckenberger M, Curioni-Fontecedro A. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiat Oncol. 2018;13:102.
31. Yuan Z, Fromm A, Ahmed KA, et al. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1-negative metastatic squamous cell carcinoma of the lung. J Thorac Oncol. 2017;12:e135-e136.
32. Komatsu T, Nakamura K, Kawase A. Abscopal effect of nivolumab-refractory immune response in a patient with primary lung cancer. J Thorac Oncol. 2017;12:e143-e144.
33. Lee SS, Morgenstern L, Phillips EH, Hiatt JR, Margulies DR. Splenectomy for splenic metastases: A changing clinical spectrum. Am Surg. 2000;66:837-840.
34. Tang H, Huang H, Xia Q, Shi Z. Isolated splenic metastasis from lung cancer: Ringleader of continuous fever. Eur Respir Rev. 2010;19:253-256.
35. Barney BM, Olivier KR, Macdonald OK, et al. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors. *Am J Clin Oncol*. 2012;35:537-542.
36. Gunvén P, Blomgren H, Lax I, Levitt SH. Curative stereotactic body radiotherapy for liver malignancy. *Med Oncol*. 2009;26:327-334.
37. Chen D, Meng X, Zhao Y, Wu S. Isolated splenic metastasis from a thymic carcinoma: A case report. *Cancer Biol Ther*. 2016;17:911-914.
38. Saito T, Toya R, Yoshida N, et al. Spleen dose-volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer. *In Vivo*. 2018;32:1519-1525.
39. Liu J, Zhao Q, Deng W, et al. Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. *Radiat Oncol*. 2017;12:90.
40. Chadha AS, Liu G, Chen H-C, et al. Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy? *Int J Radiat Oncol Biol Phys*. 2017;97:323-332.
41. Alonso C, McMullen TP, Larner JM, Wijesooriya K. Treatment-related lymphopenia is an independent predictor of survival in patients with lung cancer treated via stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2018;102:e669.
42. Dailey MO, Coleman CN, Kaplan HS. Radiation-induced splenic atrophy in patients with Hodgkin’s disease and non-Hodgkin’s lymphomas. *N Engl J Med*. 1980;302:215-217.
43. Coleman CN. Functional hyposplenia after splenic irradiation for Hodgkin’s disease. *Ann Intern Med*. 1982;96:44.
44. Onderdonk BE, Luke JJ, Bhave SR, et al. Multi-site SBRT and sequential pembrolizumab: Treated metastasis control and immune-related expression predict outcomes. *Int J Radiat Oncol Biol Phys*. 2019;104:1190-1191.
45. Ishibashi N, Maebayashi T, Aizawa T, et al. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma. *Hematology*. 2015;20:203-207.